Psychedelics company ATAI raises $125 million Series C funding round - Business Insider

📆 08/04/42 09:27 م
📰 BusinessInsider

⏱ Reading Time:
20 sec. here
2 min. at publisher
📊 Quality Score:
News: 11%
Publisher: 51%

المملكة العربية السعودية أخبار أخبار

المملكة العربية السعودية أحدث الأخبار,المملكة العربية السعودية عناوين

A major psychedelics company just landed a record sum of cash from VCs. The CEO told us how he raised the mega-round and why it's a sign psychedelics are going mainstream.

In this Friday, May 24, 2019 photo a vendor bags psilocybin mushrooms at a pop-up cannabis market in Los Angeles.ATAI Life Sciences closed a $125 million Series C round, marking the biggest funding round to date in the psychedelics space.

ATAI invests in and acquires companies looking to develop medicines for mental-health conditions from psychedelics like psilocybin, arketamine, and ibogaine. The round announced Monday came from investors including Thiel, Galaxy, Falcon Edge Capital, Catalio Capital Management, and ATAI founder Christian Angermayer's family office Apeiron Investment Group.The CEO of a $1.

اكتب تعليق

wow

لقد قمنا بتلخيص هذا الخبر حتى تتمكن من قراءته بسرعة. إذا كنت مهتمًا بالأخبار، يمكنك قراءة النص الكامل هنا. اقرأ أكثر:

المملكة العربية السعودية أحدث الأخبار, المملكة العربية السعودية عناوين